---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-001704"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:43:16.479429+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunome (IMNM) completes first cohort in Phase 1b COVID-19 antibody study; seeks partner

## Summary
- First cohort of Phase 1b study of IMM-BCP-01 (COVID-19 antibody cocktail) dosed with no significant treatment-related adverse events.
- Company plans to seek a partner to continue the trial and further development of IMM-BCP-01.
- Entered into a Letter Agreement with Whitehead Institute modifying payment obligations under a 2009 license agreement with a collaborator.
- Corporate presentation dated January 2023 posted on company website for investor and partner meetings.

## SEC filing metadata
- accession: 0001104659-23-001704
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923001704/0001104659-23-001704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923001704/tm231749d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-001704
- JSON: https://secwatch.observer/filing/0001104659-23-001704.json
- Plain text: https://secwatch.observer/filing/0001104659-23-001704.txt

## Key facts
- Material Agreements
  Immunome Inc. amended Letter Agreement with Whitehead Institute for Biomedical Research (effective 2023-01-04).
  - Action: amendment
  - Agreement: license
  - Counterparty: Whitehead Institute for Biomedical Research
  - Effective: 2023-01-04
  source text: On November 17, 2022, Immunome, Inc. (the “Company”) entered into a Letter Agreement (“Letter Agreement”) with the Whitehead Institute for Biomedical Research (“Whitehead”), which became effective on January 4, 2023 upon the satisfaction of the conditions described therein. The Letter Agreement supplements the Exclusive Patent License Agreement entered into between the Company and Whitehead on June 25, 2009 (as amended on December 17, 2009, March 21, 2013, August 21, 2017 and July 21, 2020, the “License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923001704/0001104659-23-001704-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.